Hybrid Nano-Bio Platforms: Synergistic Strategies Combining Probiotic Metabolites and Nanocarriers Against Multidrug-Resistant Pathogens

Multidrug-resistant (MDR) bacterial infections are becoming more common, which is a serious global health concern that calls for innovative antimicrobial approaches that go beyond traditional antibiotic treatments. In order to improve antibacterial efficacy, this review carefully investigates hybrid nano-bio platforms that combine probiotic-derived metabolites with nanoscale delivery technologies in a synergistic manner. Despite having natural antibacterial, antibiofilm, and immunomodulatory properties, probiotic metabolites such as bacteriocins, biosurfactants, organic acids, and reuterin are clinically limited because of their poor stability and lack of targeted administration. By enhancing bioavailability, stability, and permitting controlled, stimuli-responsive release, encapsulation within nanocarriers such polymeric nanoparticles, liposomes, solid lipid nanoparticles, and metallic nanostructures overcomes these difficulties. These hybrid systems restore antibiotic sensitivity and increase pathogen clearance by acting through a variety of antibacterial mechanisms, such as membrane rupture, efflux pump inhibition, biofilm penetration, and immunological modulation. Stimuli-responsive designs maximise therapeutic specificity while reducing off-target toxicity by enabling precise drug release in response to microenvironmental cues such as pH changes or oxidative stress. Translational obstacles still exist despite encouraging preclinical studies showing strong and long-lasting antibacterial activities with excellent biocompatibility characteristics. These include issues with thorough safety evaluations, regulatory classification, and scalable production. The development of adaptive, multifunctional, and safe next-generation antimicrobials that can successfully combat MDR pathogens and stop the global antibiotic resistance crisis is made possible by the interdisciplinary integration of microbial biotechnology and nanomedicine, which is embodied in hybrid nano-bio platforms.